Skip to main content
    A

    Avita Medical Ltd (RCEL)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $15.77
    +0.55 (+3.61%)

    Market Cap: $478.22M

    Last updated: Nov 17, 2026 at 4:15 PM ET

    Avita Medical Ltd (RCEL) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Avita Medical (RCEL) has a market cap of $478.22M and an enterprise value of $517.85M. Its share count is up 8.71% from a year earlier. It kept -42.65% of revenue as net income over the last 12 months.

    Total Valuation

    Enterprise value is 8.29% above the market cap, as debt exceeds cash.

    Market Cap$478.22M
    Enterprise Value$517.85M
    Latest price (Nov 17, 2026)$15.77

    Key Dates

    The next earnings report is expected on Feb 10, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateFeb 10, 2027 (expected)
    Last Earnings DateNov 5, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 0.38% in the quarter ended Sep 30, 2026 and grew 8.99% a year over 2 years.

    Shares Outstanding30.87M
    Shares Change (YoY)+8.71%
    Shares Change (QoQ)+0.38%
    Share Count Growth (2Y CAGR)+8.99%

    Valuation Ratios

    The price to sales ratio is 5.7x. Its year-end P/S ranged from 1.3x to 10.1x from 2021 to 2025.

    P/S Ratio5.7x
    Forward P/S3.5x

    Price Statistics

    The stock is up 320.53% over 52 weeks and trades 16.04% above its 50-day average.

    Beta (1Y)1.57
    52-Week Change+320.53%
    1-Month Change+20.02%
    3-Month Change+52.51%
    6-Month Change+275.92%
    5-Year Change-4.98%
    Total Return (1Y)+320.53%
    Total Return (3Y CAGR)+7.77%
    Total Return (5Y CAGR)+0.48%
    Return vs SPY (1Y)+287.68%
    Max Drawdown (1Y)-32.65%
    Max Drawdown (3Y)-82.14%
    Sharpe Ratio (1Y)1.65
    Correlation with SPY (1Y)0.26
    50-Day Average$13.59
    200-Day Average$7.27
    52-Week Range$3.22 to $18.43
    RSI (14 Days)54.0
    Average Volume (20 Days)612.94K

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 1.20x current liabilities.

    Current Ratio1.20x
    Quick Ratio0.99x
    Interest Coverage-5.42x

    Returns and Efficiency

    Return on invested capital is -159.34% over the last 12 months, against a 5-year average of -71.73%.

    Return on Assets (ROA)-77.18%
    Return on Invested Capital (ROIC)-159.34%
    Return on Capital Employed (ROCE)-128.08%
    ROIC (5Y Average)-71.73%
    Asset Turnover1.53x
    Inventory Turnover2.96x
    Receivables Turnover8.38x
    Cash Conversion Cycle29 days

    Scores

    RCEL has an Altman Z-Score of -9.42, in the distress zone below 1.81, and a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.

    Altman Z-Score-9.42
    Altman Z ZoneDistress
    Piotroski F-Score3 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue of $84.68M over the last 12 months is up 16.97% from the 12 months before.

    Revenue$84.68M
    Revenue Growth (YoY)+16.97%
    Gross Profit$69.75M
    Operating Income-$28.69M
    Pretax Income-$36.05M
    Net Income-$36.12M
    EBITDA-$28.11M
    EBIT-$30.43M
    Reported EPS (TTM)-$1.47

    Trailing 12 months through Sep 30, 2026.

    Balance Sheet

    Cash and Equivalents$10.50M
    Total Debt$50.13M
    Net Debt$39.63M
    Net Debt Per Share$1.28
    Working Capital$4.64M
    Shareholder Equity-$31.04M
    Tangible Book Value-$36.59M
    Total Assets$46.79M
    Total Liabilities$77.83M

    Balance sheet as of Sep 30, 2026.

    Cash Flow

    After $277.00K of capital spending, operating cash flow left -$19.99M of free cash flow.

    Operating Cash Flow-$19.72M
    Capital Expenditures$277.00K
    Free Cash Flow-$19.99M
    FCF Per Share-$0.64
    Depreciation and Amortization$2.73M

    Trailing 12 months through Sep 30, 2026.

    Margins

    The operating margin is -33.88%.

    Gross Margin82.36%
    Operating Margin-33.88%
    Pretax Margin-42.57%
    Net Margin-42.65%
    EBITDA Margin-33.20%
    EBIT Margin-35.93%
    FCF Margin-23.61%

    Dividends and Yields

    RCEL does not pay a dividend. Its free cash flow yield is -4.11%.

    FCF Yield-4.11%
    Shareholder Yield0.00%

    Stock Splits

    The last split was a 1-for-5 reverse split on Jun 30, 2020.

    Last Split DateJun 30, 2020
    Split TypeReverse split
    Split Ratio1:5

    Peer Position

    Against 12 similar companies, RCEL has the 3rd highest P/S.

    P/S Ratio5.7x vs 1.8x median
    ROIC-159.34% vs -0.17% median
    Revenue Growth (Trailing 4 Quarters, YoY)+16.97% vs +14.21% median

    Competitors compared

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About RCEL

    What is RCEL's market cap?

    Avita Medical has a market cap of $478.22M. Its enterprise value, which adds debt and subtracts cash, is $517.85M.

    How many shares of RCEL are outstanding?

    Avita Medical has 30.87M shares outstanding. The count is up 8.71% from a year earlier.

    Does RCEL pay a dividend?

    No. Avita Medical does not pay a dividend.

    How much debt does RCEL have?

    Avita Medical has $50.13M of total debt and $10.50M of cash and equivalents, a net debt position of $39.63M.